Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
The era of personalized medicine is already well established in oncology. Biomarker-driven targeted therapies are among the top-selling oncology products today, and the impact of molecular…
Despite the comparatively low incidence of chronic myeloid leukemia (CML) in the United States, patient management requires extended durations of therapy, which in turn translates into a…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…